clinical_trials
Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD
Confidence86·multiple reportsImportance88NP-EVT-20261107-1884F1B
(MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and...
Read the original at the primary source
Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD
11/7/2026, 10:15:26 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —